Moving the Needle on Alzheimer’s Disease with an Anti-Oligomer Antibody

In the current issue of the Journal, van Dyck and colleagues1 report the encouraging results of an 18-month, phase 3 trial of lecanemab that involved participants with early Alzheimer’s disease. The primary end point was the change from baseline in the score on the Clinical Dementia Rating–Sum of Boxes. Key secondary end points were the change from baseline in amyloid burden as assessed by means of positron emission tomography, the score on the 14-item cognitive subscale of the Alzheimer’s Disease Assessment Scale, the Alzheimer’s Disease Composite Score, and the score on the Alzheimer’s Disease Cooperative Study–Activities of Daily Living Scale . . .